The move centers on the devices’ blood-oxygen sensor.
Apple will halt sales of new models of its smartwatch due to a patent dispute, the company announced on Monday.
The move, which affects Apple Watch Series 9 and Apple Watch Ultra 2, centers on the devices’ blood-oxygen sensor.
In October, a federal trade agency found that Apple violated the patent of California-based medical technology company Masimo. The ruling set off a 60-day review period for the Biden administration, which ends on Dec. 25.
Apple has decided to preemptively stop sales of the smartwatches, the company said.
“Apple’s teams work tirelessly to create products and services that empower users with industry-leading health, wellness, and safety features,” according to the company’s statement. “Apple strongly disagrees with the order and is pursuing a range of legal and technical options to ensure that Apple Watch is available to customers.”
On Dec. 21, the company will halt sales of new smartwatch models online. Retail stores will also stop selling the smartwatches on Dec. 24. Sales of the smartwatches will continue outside of the U.S., Apple noted.
Separately, Apple has accused Massimo of stealing patented features from Apple for its smartwatch.
Masimo did not immediately respond to a request for comment.
Released in September, the Apple Watch Series 9 ranges in price from $399 to $749.
On its website, Apple calls the device’s blood-oxygen sensor a “breathtaking innovation.”
Jessica Irvine is a tech enthusiast specializing in gadgets. From smart home devices to cutting-edge electronics, Jessica explores the world of consumer tech, offering readers comprehensive reviews, hands-on experiences, and expert insights into the coolest and most innovative gadgets on the market.
